Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13165979 | 1.00 | TRPA1 (0.53) | TRPA1MAOAMAOBLMNATDP1 | |
| SCHEMBL13165980 | 1.00 | TRPA1 (0.53) | TRPA1MAOAMAOBLMNATDP1 | |
| SCHEMBL19231862 | 0.83 | TRPA1 (0.50) | TRPA1MAOAMAOBLMNATDP1 | |
| SCHEMBL22257241 | 0.83 | TRPA1 (0.50) | TRPA1MAOAMAOBLMNATDP1 | |
| SCHEMBL24244793 | 0.82 | TRPA1 (0.53) | TRPA1MAOAMAOBLMNAIDO1 | |
| SCHEMBL15161169 | 0.81 | TP53 (0.42) | TRPA1TDP1TAAR1PPARG | |
| SCHEMBL18567215 | 0.81 | TRPA1 (0.44) | TRPA1MAOAMAOBTDP1LOXL2 | |
| SCHEMBL1011189 | 0.80 | TRPA1 (0.52) | TRPA1MAOAMAOBIDO1LOXL2 | |
| SCHEMBL8522755 | 0.80 | TRPA1 (0.68) | TRPA1MAOAMAOBIDO1LOXL2 | |
| SCHEMBL3932320 | 0.80 | TRPA1 (0.68) | TRPA1MAOAMAOBIDO1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220741-A1 | ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF | DICE MOLECULES SV, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230365531-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMO VIRUS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3438095-B1 | PYRIDAZINONE COMPOUND OR ITS SALT, AND HERBICIDE CONTAINING IT | ISHIHARA SANGYO KAISHA (JP) | 2021-06-16 | — | — | EP | disclosed |
| WO-2021080511-A1 | METHODS OF BORYLATION AND USES THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2021-04-29 | — | — | WO | disclosed |
| US-10934283-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-9551721-B2 | Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-01-24 | — | — | US | disclosed |
| US-8883824-B2 | 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20120142748-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| WO-2010149684-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-29 | — | — | WO | disclosed |
| EP-0107492-B1 | HELICHROMIC-SMECTIC LIQUID CRYSTAL COMPOSITIONS AND DISPLAY CELLS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-08-09 | — | — | EP | disclosed |
| EP-0044666-B1 | HELICHROMIC COMPOUNDS AND DISPLAYS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1985-05-29 | — | — | EP | disclosed |
| US-4514045-A | DICHROISM; COMPLETE LIGHT ABSORPTION; LOW VOLTAGE; CONTRAST | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1985-04-30 | — | — | US | disclosed |
| EP-0107492-A2 | Helichromic-smectic liquid crystal compositions and display cells | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1984-05-02 | — | — | EP | disclosed |
| EP-0044666-A2 | Helichromic compounds and displays | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1982-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4F11, WEE1 | TRPA1 2379/4885MAOA 3707/4885MAOB 2823/4885 |
| US-20120142748-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | CNR1, CNR2, GPR18 | TRPA1 395/4885MAOA 2524/4885MAOB 2144/4885 |
| US-20230365531-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMO VIRUS | METAP1, SARS1, RTF1 | TRPA1 4858/4885MAOA 2475/4885MAOB 1698/4885 |
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | TRPA1 4588/4885MAOA 2764/4885MAOB 1413/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | TRPA1 4588/4885MAOA 2764/4885MAOB 1413/4885 |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACSL3, SLCO4C1, SLC38A7 | TRPA1 962/4885MAOA 534/4885MAOB 737/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | TRPA1 4742/4885MAOA 1008/4885MAOB 648/4885 |
| US-10934283-B2 | COMT inhibiting methods and compositions | COMT, MAOB, MAOA | TRPA1 4066/4885MAOA 3/4885MAOB 2/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | TRPA1 4588/4885MAOA 2764/4885MAOB 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.